Kaplan-Meier estimate of event-free survival and cumulative incidence of relapses of SR patients by ALL-BFM 95 risk criteria (“SR-95”) in trials ALL-BFM 90 and 95 according to sex. Patients of ALL-BFM 95 received 2 doses of daunorubicin in induction, patients of ALL-BFM 90 4 doses. Duration of maintenance was 36 months for boys of ALL-BFM 95 and 24 months for the remaining patients. “SR-95” indicates standard risk by ALL-BFM 95 criteria; Ev, number of events; Rel, number of relapses; 6y-pEFS, probability of event-free survival at 6 years; 6y-CI, cumulative incidence of relapses at 6 years; SE, standard error.